Compare Lam Research Corporation (LRCX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Tenet Healthcare Corporation — how do they compare? Lam Research Corporation trades at $326.94 (market cap $389.67B), while Tenet Healthcare Corporation trades at $263.56 (market cap $20.89B). The key difference: Lam Research Corporation is far larger — about 18.7× Tenet Healthcare Corporation's market cap, and Lam Research Corporation pays a 0.33% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| LRCX | THC | |
|---|---|---|
Market Cap | $389.67B | $20.89B |
Sector | Technology | Health |
52-Week High | $433.33 | $262.63 |
52-Week Low | $97.03 | $161.37 |
Enterprise Value | $387.83B | $31.97B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $306.4, down 1.59% on the day, with a neutral technical signal. The company shows strong fundamentals, including a 31.27% net income margin and three consecutive quarterly EPS beats. Recent news highlights expansion into panel-level packaging and workforce development collaborations, supporting growth in the AI-driven semiconductor equipment sector.
Outlook remains positive with a consensus price target of $397.18, implying significant upside. Risks include competitive pressures from new entrants like SpaceX's Terafab and reliance on AI chip demand cycles. Analyst sentiment is strongly bullish with 78% buy ratings, but investors should monitor execution against high valuation multiples.
Tenet Healthcare (THC) trades at $260.67, up 0.28% today, with strong technical momentum including a golden cross pattern and bullish moving average alignment. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.12 versus $4.26 forecast, maintaining a three-quarter earnings beat streak. Valuation metrics remain attractive with P/E of 10.03 and EV/EBITDA of 5.73, while profitability metrics show exceptional ROE of 53.31% and net margin of 9.9%.
The investment outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target representing 8% upside. Key risks include policy headwinds in ACA exchanges and hospital segment challenges, though strong ambulatory growth provides offset. The stock presents a compelling value-growth combination with momentum characteristics, supported by institutional accumulation and positive earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
